Oral isotretinoin treatment in patients with acne vulgaris during the COVID-19 pandemic: A retrospective cohort study in a tertiary care hospital
Open Access
- 1 July 2021
- journal article
- research article
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 20 (7) , 1969-1974
Abstract
Background Patients with acne vulgaris continue to present increasingly in dermatology outpatient clinics and seek treatment during the COVID-19 pandemic. As far as we know, the effect of isotretinoin on COVID-19 has not been studied before. Aim We aimed to evaluate whether patients receiving oral isotretinoin are at increased risk of COVID-19 infection by comparing them with patients on topical treatment for acne vulgaris. Methods The data were collected retrospectively from a cohort of 267 acne vulgaris patients, who were under follow-up for acne vulgaris treatment during the pandemic period. Results Total of 227 patients (141 receiving isotretinoin treatment and 86 receiving topical treatment) were included of whom 29 patients had COVID-19 infection during acne vulgaris treatment. Fifteen (10.6%) patients were receiving oral isotretinoin and 14 (16.3%) were receiving topical acne treatment at the time of COVID-19 infection. The mean cumulative dose was 2340 +/- 1988 mg at the time of COVID-19 infection. The mean elapsed time between the onset of isotretinoin treatment and positive PCR result for COVID-19 was 13.3 +/- 10.3 weeks. Nine patients (64.3%) receiving isotretinoin treatment and 9 patients (60%) under topical treatment had loss of taste and smell during COVID-19 infection. Isotretinoin treatment was not found to be associated with a significant increased risk of getting COVID-19 (odds ratio, 0.671; 95% confidence interval, 0.247-1.823; P = 0.434). Conclusion As a conclusion, the results of this study encourage dermatologists and acne vulgaris patients to initiate oral isotretinoin treatment safely during the pandemic period.Keywords
This publication has 16 references indexed in Scilit:
- The immediate impact of COVID-19 on US dermatology practicesJournal of the American Academy of Dermatology, 2020
- Systemic isotretinoin therapy in the era of COVID‐19Dermatologic Therapy, 2020
- Could patients taking isotretinoin therapy be immune against SARS‐CoV ‐2?Dermatologic Therapy, 2020
- The effect of the “stay‐at‐home” policy on requests for dermatology outpatient clinic visits after the COVID ‐19 outbreakDermatologic Therapy, 2020
- Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methodsActa Pharmaceutica Sinica B, 2020
- Effects of isotretinoin on the olfactory function in patients with acneAnais Brasileiros de Dermatologia, 2017
- Guidelines of care for the management of acne vulgarisJournal of the American Academy of Dermatology, 2016
- Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesisThe Journal of Pathology, 2004
- Taste and olfactory disturbances after treatment for acne with isotretinoin, a 13-cis-isomer of retinoic acidEuropean Archives of Oto-Rhino-Laryngology, 1990
- Treatment of acne vulgaris.1958